Cargando…
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)
MicroRNAs were described to target mRNA and regulate the transcription of genes involved in processes de-regulated in tumorigenesis, such as proliferation, differentiation and survival. In particular, the miRNA let-7 has been suggested to regulate the expression of the KRAS gene, a common mutated ge...
Autores principales: | Ganzinelli, Monica, Rulli, Eliana, Caiola, Elisa, Chiara Garassino, Marina, Broggini, Massimo, Copreni, Elena, Piva, Sheila, Longo, Flavia, Labianca, Roberto, Bareggi, Claudia, Agnese Fabbri, Maria, Martelli, Olga, Fagnani, Daniele, Cristina Locatelli, Maria, Bertolini, Alessandro, Valmadre, Giuseppe, Pavese, Ida, Calcagno, Anna, Giuseppa Sarobba, Maria, Marabese, Mirko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648064/ https://www.ncbi.nlm.nih.gov/pubmed/26573509 http://dx.doi.org/10.1038/srep16331 |
Ejemplares similares
-
The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016) -
Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells
por: Sabatino, Maria Antonietta, et al.
Publicado: (2010) -
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
por: Marabese, Mirko, et al.
Publicado: (2015) -
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018) -
Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
por: Caiola, Elisa, et al.
Publicado: (2018)